General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Novartis Corporation(SIGNIFICANT), AstraZeneca Pharmaceuticals(SIGNIFICANT), Regeneron(SIGNIFICANT), Abbott Laboratories(SIGNIFICANT), Alnylam(SIGNIFICANT), biofourmis(SIGNIFICANT), Merck & Co., Inc.(MODEST), Cytokinetics(MODEST), Verily(MODEST), Avidity Biopharma(SIGNIFICANT), Axon Therapeutics(SIGNIFICANT), GlaxoSmithKline(SIGNIFICANT), medpace(MODEST), Parexel(SIGNIFICANT), New Amsterdam(MODEST), scPharma(MODEST), Roche(MODEST) RESEARCH/RESEARCH GRANTS: Novartis Corporation(SIGNIFICANT), AstraZeneca Pharmaceuticals(SIGNIFICANT), Alnylam(SIGNIFICANT), Bayer Healthcare Pharmaceuticals(NONE), Pfizer Inc(NONE) OTHER FINANCIAL BENEFIT: TIMI Study Group(SIGNIFICANT), Baim Clinical Research Institute(SIGNIFICANT)

View Full Disclosure